As movement restrictions continue in the Hubei province where COVID-19 was first confirmed in late December, advisories are now growing to other parts of Asia, and countries including Iran and Italy. Mitigation and risk management plans are now being implemented by US-based companies, including a recent companywide travel and meetings policy designed to reduce potential disruption from coronavirus at Vertex in Cambridge, Mass. In light of pandemic planning, Veeva Systems is extending users of its CRM system free six-month access to its product Engage Meeting, a product designed to enhance HCP-to-sales rep communication.
Paul Shawah, Senior Vice President, Commercial Strategy at Veeva Systems, told Pharmaceutical Executive that Engage Meeting operates as an add-on to Veeva CRM, which offers web-based audio, video and content sharing capabilities aligned with the customer details in the CRM, ie., their affiliation, specialty, to share information in a compliant manner. Shawah said, “Some of our customers already had plans to add Engage Meeting as part of their overall strategies, not as part of this acute situation. But we thought it would be the right thing to do to help our customers.” To that end, parts of Veeva’s business teams have been temporarily re-aligned to get their customers up and running.
Shawah said that a customer in China was able to get more than 2,000 users up and running within eight days. Most of that time is not spent with the actual technology implementation, however, it is a change for sales representatives used to calling on HCPs in a face-to-face setting to use email to schedule a call. According to Shawah, Engage Meeting will help pharma companies during this crisis to continue to educate HCPs about therapies that will help patients. For example, says Shawah, oncology therapies evolve quickly, and getting that information even to physicians who are unable to meet face-to-face with sales reps and receive updated educational materials will be helpful during this time.
After the six-month period, in which Shawah expressed hope that the global situation will have resolved, companies that have taken advantage of Engage Meeting can discontinue usage with no additional charges. However, with 12,000 reps across six major pharma companies that have gone live in the past two weeks, most of which were part of the “already planning to implement” group that Shawah mentioned, it may be that sales reps find the increased time encounters on the platform-on average 15 minutes vs. two minutes in person-a welcome change.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
2 Commerce Drive
Cranbury, NJ 08512